What is the rationale for monitoring secondary malignancies after BCMA and CD19 CAR T-cell therapy?

The Lymphoma Hub and Multiple Myeloma were pleased to speak to Anna Sureda, Catalan Institute of Oncology, Barcelona, ES. We asked, What is the rationale for monitoring secondary malignancies after B-cell maturation antigen (BCMA) and CD19 chimeric antigen receptor (CAR) T-cell therapy?

In this interview, Anna Sureda discusses the latest data on the incidence of secondary malignancies after treatment with CAR T-cell therapies, sharing their insight on the implications of these data for clinical practice. Sureda shares considerations for CAR T-cell treatments, including the importance of balancing therapeutic benefits with potential implications for the development of secondary malignancies.